Apollomics Inc - Class A

Research Apollomics Inc - Class A (APLM) on Bullrun: market cap USD 46.65M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAPLM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 46.65M
• Financial periodQ4 2025
• RevenueUSD 8.50M
• Net income-USD 10.94M
• Free cash flow-USD 10.37M

Valuation Snapshot

latest market cap is USD 46.65M.

About Apollomics Inc - Class A

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation;

Frequently asked questions

What is Apollomics Inc - Class A's market cap?

Apollomics Inc - Class A's market capitalization is USD 46.65M.

What does Apollomics Inc - Class A do?

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.